Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2

Cancer Research

Volumn 60, Issue 13, 2000, Pages 3384-3388

  Klapper, Leah N ^a   Waterman, Hadassa ^a   Sela, Michael ^a   Yarden, Yosef ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; TYROSINE KINASE RECEPTOR;

ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; DEGRADATION; EMBRYO; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MUTAGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; PROTEIN PROCESSING;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE; CHO CELLS; CONSENSUS SEQUENCE; CRICETINAE; HUMANS; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; ONCOGENE PROTEIN V-CBL; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTOR, ERBB-2; RECOMBINANT PROTEINS; RETROVIRIDAE PROTEINS, ONCOGENIC; STOMACH NEOPLASMS; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; UBIQUITINS;

EID: 0034234854     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Tzahar, E., and Yarden, Y. The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands. Biochem. Biophys. Acta. Rev. Cancer. 1377: M25-M37, 1998.
2. Hynes, N. E., and Stern, D. F. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochem. Biophys. Acta, 1198: 165-184, 1994.
3. Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J., Rosen, P. P., Twaddell, T., Henderson, I. C., and Norton, L. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol., 14: 737-744, 1996.
4. Slamon, D., Levland-Jones, B., and Shak, S. E. A. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MCB) markedly increases anticancer activity: a randomized, multinational controlled phase III trial. Proc. Am. Soc. Clin. Oncol., 17: 98a, 1998.
5. Klapper, L. N., Vaisman, N., Hurwitz, E., Pinkas Kramarski, R., Yarden, Y., and Sela, M. A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors. Oncogene, 14: 2099-2109, 1997.
6. Kasprzyk, P. G., Song, S. U., Di Fiore, P. P., and King, C. R. Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies. Cancer Res., 52: 2771-2776, 1992.
7. Hurwitz, E., Stancovski, I., Sela, M., and Yarden, Y. Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake. Proc. Natl. Acad. Sci. USA, 92: 3353-3357, 1995.
8. Levkowitz, G., Waterman, H., Zamir, L., Kam, Z., Oved, S., Langdon, W. Y., Beguinot, L., Geiger, B., and Yarden, Y. c-Cbl/Sli-1 regulates endocytic sorting and ubiquitinatitm of the epidermal growth factor receptor. Genes Dev., 12: 3663-3674, 1998.
9. Joazeiro, C. A. P., Wing, S. S., Huang, H-K., Leverson, J. D., Hunter, T., and Liu, Y-C. The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. Science (Washington DC), 286: 309-312, 1999.
10. Levkowitz, G., Waterman, H., Ettenberg, S. A., Katz, M., Tsygankov, A. Y., Alroy, I., Lavi, S., Iwai, K. Reiss, Y., Ciechanover, A., Lipkowitz, S., and Yarden, Y. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol. Cell, 4: 1029-1040, 1999.
11. Thien, C. B. F., and Langdon, W. c-Cbl: a regulator of T cell receptor-mediated signaling. Immunol. Cell Biol., 76: 473-482, 1998.
12. Miyake, S., Lupher, M. L., Jr. Druker, B., and Band, H. The tyrosine kinase regulator Cbl enhances the ubiquitination and degradation of the platelet-derived growth factor receptor α. Proc. Natl. Acad. Sci. USA, 95: 7927-7932, 1998.
13. Worthylake, R., Opresko, L. K., and Wiley, H. S. ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. J. Biol. Chem., 274: 8865-8874, 1999
14. Lenferink, A. E., Pinkas Kramarski, R., van de Poll, M. L., van Vugt, M. J., Klapper, I., N., Tzahar, E., Waterman, H., Sela, M., van Zoelen, E. J., and Yarden, Y. Differential endocytic routing of homo-and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J., 17: 3385-3397, 1998.
15. Magnifico, A., Tagliabue, E., Ardini, E., Casalini, P., Colnaghi, M. I., and Menard, S. Heregulin β1 induces the down-regulation and the ubiquitin-proteasome degradation pathway of p185HER2 oncoprotein. FEBS Lett., 422: 129-131, 1998.
16. Weiner, D. B., Liu, J., Cohen, J. A., Williams, W. V., and Greene, M. I. A point mutation in the neu oneogene mimics ligand induction of receptor aggregation. Nature (Lond.), 339: 230-231, 1989.
17. Muthuswamy, S. K., Gilman, M., and Brugge, J. Controlled dimerization of ErbB receptors provide evidence for differential signaling by homo-and heteriodimers. Mol. Cell. Biol., 19: 6845-6857, 1999.
18. Meng, W., Sawasdikosol, S., Burakoff, S. J., and Eck, M. J. Structure of the amino-terminal domain of Cbl complexed to its binding site on ZAP-70 kinase. Nature (Lond.), 398: 84-90, 1999.
19. Mimnaugh, E. G., Chavany, C., and Neckers, L. Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J. Biol. Chem., 271: 22796-22801, 1996.
20. Levkowitz, G., Klapper, L. N., Tzahar, E., Freywald, A., Sela, M., and Yarden, Y. Coupling of the c-Cbl protooncogene product to ErbB-1/EGF-receptor but not to other ErbB proteins. Oncogene, 12: 1117-1125, 1996.
21. Murphy, M. A., Sehnall, R. G., Venter, D. J., Barnett, L., Bertoncello, I., Thien, C. B., Langdon, W. Y., and Bowtell, D. D. Tissue hyperplasia and enhanced T-cell signalling via ZAP-70 in c-Cbl-deficient mice. Mol. Cell. Biol., 18: 4872-4882, 1998.